Table 1 Comparison of various clinical characteristics between the PJP and the non-PJP groups
Non-PJP group (n = 84) | PJP group (n = 28) | P-value | |
|---|---|---|---|
Age at time of transplant (years) | 46.2 | 52.5 | 0.03* |
Female (%) | 44.0 | 28.6 | 0.17 |
Non-white (%) | 9.5 | 25.0 | 0.07 |
Living donor transplants (%) | 47.6 | 32.1 | 0.14 |
History of prior transplantation (%) | 21.4 | 15.4 | 0.41 |
Induction immunosuppression | 0.22 | ||
- None | 13.1 | 7.7 | |
- Basiliximab | 36.9 | 65.4 | |
- Thymoglobulin | 21.4 | 7.7 | |
- Alemtuzumab | 13.1 | 19.2 | |
- Other | 15.5 | 0 | |
HLA mismatch | 2.7 | 3.9 | 0.005* |
- HLA mismatch > 3 (%), with 3 being the median for the entire group | 35.7 | 65.4 | |
Delayed graft function (%) | 11.9 | 14.3 | 0.76 |
BK viremia (%) | 6.0 | 21.4 | 0.01* |
CMV viremia (%) | 6.0 | 35.7 | < 0.001* |
Biopsy proven rejection (%) | 29.8 | 39.3 | 0.41 |
Invasive fungal infections (%) | 1.2 | 7.1 | 0.01* |
Clostridium difficile or norvirus diarrheal illness (%) | 2.4 | 10.7 | 0.11 |
- Norovirus (%) | 0 | 3.6 | |
- Clostridium difficile (%) | 2.4 | 7.1 |